Furthermore, rBCG-S1PT improved activation markers on CD4+ T cells and exerted greater cytotoxicity against MB49 bladder cancer cells, suggesting it could potentially be an enhanced immunotherapy for bladder cancer. The gene discussed is CD4; the disease is urinary bladder carcinoma.